A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

Timeframe for evaluation of this outcome measure is Baseline (BL), M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI)

This outcome assesses the change in IAM score for SSPs over time. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI) compared to BL.

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ at baseline are displayed in this outcome measure. In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.

SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.

SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs indicated their level of concern (ranging from "Not at all concerned" to "Extremely concerned") regarding identifying eligible individuals for APRETUDE, staff resourcing to ensure appropriate clinic flow, number of exam rooms for injections and clinic staff to administer injections.

SSP perceptions on the appropriateness of APRETUDE gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). In this Outcome Measure SSPs evaluated staff sufficiency to manage the current or anticipated number of APRETUDE patients on an ongoing basis.

Semi-structured interview (SSI) guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

The IAM was used to assess the appropriateness of APRETUDE for PSPs using a four-item measure (1. APRETUDE seems fitting for me, 2. APRETUDE seems suitable for my lifestyle, 3. APRETUDE seems applicable in my life, 4. APRETUDE seems like a good match) with a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5, with 1 indicating the least appropriate and 5 the most appropriate. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).

This outcome assesses the change in IAM for PSPs over time. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI) compared to BL.

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE for PSPs gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSP perceptions on the appropriateness of APRETUDE for patients, including specific patient groups or characteristics influencing appropriateness.

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. The number of SSPs reporting in the ISQ that APRETUDE is more appropriate for specific patient demographic groups is displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions of the appropriateness of APRETUDE for specific patient demographics groups as reported in the ISQ are displayed in this outcome measure. Timeframe for evaluation is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the appropriateness of APRETUDE for PSPs gathered through the ISQ are displayed in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). In this outcome measure, appropriateness of APRETUDE for patients was reported by SSPs by rating in the ISQ their level of concern (ranging from "Not at all concerned" to "Extremely concerned") surrounding patients' belief in the efficacy of APRETUDE and experience with pain.

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSPs perceptions on the appropriateness of APRETUDE gathered during SSIs at baseline are displayed. This outcome measure presents common concepts identified from qualitative analysis of PSPs' perceived appropriateness of APRETUDE. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. The number of PSPs who completed the Sexual Health Assessment tool (available only to the ECI arm) are displayed by gender. Per protocol planned analysis, data for this outcome measure was to be collected via PreRP Information Questionnaire. Data was however collected from PSPs via ISQ due to a programming error in the PrEP Information Questionnaire. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. The number of PSPs who completed the Sexual Health Assessment tool (available only to the ECI arm) are displayed by clinic type to represent differences across clinical settings. Per protocol planned analysis, data for this outcome measure was to be collected via PreRP Information Questionnaire. Data was however collected from PSPs via ISQ due to a programming error in the PrEP Information Questionnaire. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.

Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.

Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.

Overall estimates for PrEP adoption at participating clinics were obtained via the PrEP Information Questionnaire. The timeframe for evaluation of this outcome measure is through M12.

The FIM was used to assess the feasibility of the PrEP training provided only to EI and ECI arms using a four-item measure (1. The PrEP training would be easily implemented as part of my continuing education 2. It would be possible to incorporate the PrEP training into my continuing education efforts 3. The PrEP training was doable as a continuing education activity 4. The PrEP training was easy to use) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score ranges from 1 to 5 with 1 indicating the least feasibility and 5 the most feasibility. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI); and was not assessed at baseline as sites had not had time to utilize the tool.

This outcome assesses the change in FIM score for PrEP Training for SSPs over time. The change in FIM score was calculated as the longitudinal mean change from Month 4 to Month 12. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI) compared to M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of study tools gathered through the ISQ at BL, M4, and M12 are displayed. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents SSPs'perception of ease of implementation of the PrEP Options Communication Tool and of the Sexual Health Assessment Tool.

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the planned frequency of use of the PrEP Options Communication Tool and of the Sexual Health Assessment Tool among SSPs' clinics.

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs' perception of PrEP training ease of use, of the amount of time involved in using the PrEP training, of ease of implementation of the PrEP Options Communication Tool (question for EI SSPs only) and of ease of implementation of the Sexual Health Assessment Tool (question for ECI SSPs only).

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs' perception of PrEP training ease of use, of the amount of time involved in using the PrEP training, of ease of implementation of the PrEP Options Communication Tool (question for EI SSPs only) and of ease of implementation of the Sexual Health Assessment Tool (question for ECI SSPs only).

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This Outcome Measure presents the SSP's perception of frequency of using the PrEP Options Communication Tool with each patient (question for EI SSPs only) and Frequency of using the Sexual Health Assessment Tool with each patient (question for ECI SSPs only).

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This Outcome Measure presents the SSP's perception of frequency of using the PrEP Options Communication Tool with each patient (question for EI SSPs only) and Frequency of using the Sexual Health Assessment Tool with each patient (question for ECI SSPs only).

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reason the PrEP Options Communication Tool was not used by a clinic/practice.

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reason the PrEP Options Communication Tool was not used by a clinic/practice.

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reasons the Sexual Health Assessment Tool was not used by a clinic/practice.

Tools were only available to select arms, and detailed feasibility information was only collected for a subgroup of the tools provided. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the reasons why the Sexual Health Assessment Tool was not used by a clinic/practice.

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSPs perceptions on the feasibility and utility of study tools were gathered. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the number of SSPs who found the specified tools and resources useful.

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSPs perceptions on the feasibility and utility of study tools were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the number of SSPs who found the specified tools and resources useful.

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on if study tools were fit for use were gathered. Tools were only available to selected arms.Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the usage of the specified tools and completion of the PrEP Education Training (PrEPare for Black Women).

Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSPs perception of the helpfulness of the specified tools.

PrEP training and tools were only available to selected arms (EI and/or ECI). Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs agreement with the following sentences: "The PrEP training would be useful for my healthcare practice", "The PrEP training helped me address my patients' HIV prevention concerns effectively", "The PrEP Options Communication Tool helped to facilitate conversations about PrEP with patients" (EI only), "The Sexual Health Assessment Tool is an easy way to identify individuals interested in PrEP (ECI only)" and "The Sexual Health Assessment Tool helps to facilitate conversations about PrEP with patients" (ECI only).

Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the usage of the specified tools and completion of the PrEP Education Training (PrEPare for Black Women).

Tools were only available to selected arms.Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents SSPs perception of the helpfulness of the specified tools.

Tools were only available to selected arms. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs agreement with the following sentences: "The PrEP training would be useful for my healthcare practice", "The PrEP training helped me address my patients' HIV prevention concerns effectively", "The PrEP Options Communication Tool helped to facilitate conversations about PrEP with patients" (EI only), "The Sexual Health Assessment Tool is an easy way to identify individuals interested in PrEP (ECI only)" and "The Sexual Health Assessment Tool helps to facilitate conversations about PrEP with patients (ECI only)".

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies.

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials.

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies.

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials.

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement with the following questions: "Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only)" and "Did your provider or clinic staff discuss your assessment results with you? (ECI only)".

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answers to the following question: "Who discussed the results of the assessment with you? (ECI only)".

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answer in terms of helpfulness to the following question regarding the sexual health assessment: "How helpful was discussing your results with your provider or clinic staff? (ECI only)".

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the reason the Sexual Health Assessment tool was not used by PSPs.

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the usefulness of the specified APRETUDE support tools and strategies by patient gender subgroups.

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the helpfulness of the specified APRETUDE learning materials by patient gender subgroups.

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement with the following questions: "Have you completed a Sexual Health Assessment from your provider in the last 12 months? (ECI only)" and "Did your provider or clinic staff discuss your assessment results with you? (ECI only)".

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answers to the following question regarding the sexual health assessment: "Who discussed the results of the assessment with you? (ECI only)".

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs answer in terms of helpfulness to the following question regarding the sexual health assessment: "How helpful was discussing your results with your provider or clinic staff? (ECI only)".

PSP perceptions of study tools being fit for use were gathered through the ISQ. In alignment with study design, some tools were restricted to one or two arms, as noted in parentheses next to each tool below. Not all tools were assessed at all time points. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the reason the Sexual Health Assessment tool was not used by PSPs.

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSPs perceptions on the utility of study tools and strategies were gathered using SSIs. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs perception over the specified implementation tools and strategies.

PSPs perceptions on the utility of study tools and strategies were gathered using SSIs. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs perception over the specified implementation tools and strategies by patient gender subgroups.

This outcome measure evaluates the number of injections occurring within the target window. The target window is defined as +/- 7 days from target date of injection for Dose 2 and subsequent injections. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

PSP perceptions of barriers and facilitators to fidelity to APRETUDE injection windows were gathered via the ISQ. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs responses to the following question: "How easy was it to understand the Target Appointment Date?"

Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Have you missed any of your APRETUDE injection visits in the last 6 months?".

Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Was missing your APRETUDE injection visits planned or unplanned?".

Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Did you start oral PrEP after missing any of your injection visit?".

Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "How easy or difficult was it to start oral PrEP after a missed injection visit?".

Data below were collected by ISQ and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings.Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "How acceptable was it to start oral PrEP after a missed injection visit?".

Data below were collected via SSIs or interviews, and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs understanding and access to the target appointment date. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

Data below were collected via SSIs or interviews, and below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSP responses to the APRETUDE adherence and the specified barriers and facilitators to injection fidelity.

Data below were collected by ISQ and below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses for the specified items regarding patient management challenges and injection fidelity for APRETUDE.

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. Data displayed represent injection fidelity topics discussed by SSPs while describing the APRETUDE implementation process. SSIs were not conducted with SSPs at baseline. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI).

Data below were collected via SSIs, and are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents topics surrounding managing adherence and missed doses as discussed by SSPs during SSIs. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

IMCs were conducted monthly by trained qualitative researchers with one to two SSPs per study site. These calls included discussion of implementation progress, facilitators and barriers to implementation, and solutions to challenges faced. Data below summarize site-level themes related to barriers and facilitators to fidelity to APRETUDE injection windows as discussed during IMC calls. Data below are stratified by clinic type to represent difference by traditional (HIV specialty) and non-traditional (women's clinics, primary care clinics) settings. Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI).

Timeframe for evaluation of this outcome measure is through M12 (equivalent to M13 for PSPs who received OLI).

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified APRETUDE implementation and patient management. Only a selection of items are applicable for BL timepoint.

Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs response to the specified items regarding to the clinic climate and change readiness as implementation barriers and facilitators.

Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs perception of the bi-monthly injection benefits.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This endpoint presents the PSPs with responses to the specified questions regarding prior knowledge of HIV/PrEP. For each timepoint assessed for this outcome measure only specific questions were applied.

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This endpoint presents the PSPs with responses to the specified items regarding HIV knowledge and misconceptions.

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs agreement regarding the social and personal perceptions (support, stigma, attitude) towards PrEP use.

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL. This outcome measure presents the PSPs response to the following question: "In general, what kind of attitude do you think your community has toward PrEP?".

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs response to the following question: "How often are you worried that people may find out that you are taking APRETUDE?".

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the sources of information for APRETUDE pre-enrollment. This outcome measure presents the PSPs response to the following question: "If you have questions about APRETUDE, where do you find information?" The answer "the study app/website" was inconsistently displayed to study arms at different time points due to a programming error.

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). The outcome measure presents the PSPs perception of the benefits of in-person APRETUDE injection visits.

Overall PSP perceptions of the barriers, facilitators, and concerns related to receipt of APRETUDE were gathered. Timeframe for evaluation of this outcome measure is at BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the following question: "Overall, how are you feeling about getting APRETUDE?".

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall SSP perceptions of barriers, facilitators, and concerns related to APRETUDE implementation were gathered. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.

IMCs were conducted monthly by trained qualitative researchers with one to two SSPs per study site. These calls included discussion of implementation progress, facilitators and barriers to implementation, and solutions to challenges faced. Data below summarize site-level themes related to overall SSP perceptions of facilitators and barriers to APRETUDE implementation discussed during IMC calls. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to qualitative data collection.

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall PSP perceptions of facilitators and barriers to receipt of APRETUDE and its implementation were gathered. This outcome measure presents the PSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). Overall PSP perceptions of facilitators and barriers to receipt of APRETUDE and its implementation were gathered. Timeframe for evaluation of this outcome measure is at M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs responses to the specified facilitators and barriers to implementation, based on the SSI guides.

The AIM was used to assess among PSPs the acceptability of APRETUDE using a four-item measure (1. I believe APRETUDE will meet my approval for preventing HIV, 2. APRETUDE for the prevention of HIV is appealing to me, 3. I think I will like APRETUDE for the prevention of HIV, 4. I welcome APRETUDE for the prevention of HIV) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the AIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI)

The FIM was used to assess among PSPs the feasibility of APRETUDE using a four-item measure (1. Receiving APRETUDE injections every 2 months seems workable in my life, 2. Receiving APRETUDE injections every 2 months seems possible for me, 3. Receiving APRETUDE injections every 2 months seems doable in my life, 4. Receiving APRETUDE injections every 2 months seems easy in my life) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the FIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).

The AIM was used to assess the acceptability of APRETUDE using a four-item measure (1. APRETUDE in our clinic/practice meets my approval, 2. APRETUDE in our clinic/practice is appealing to me, 3. I like APRETUDE in our clinic/practice, 4. I welcome APRETUDE in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the AIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

The FIM was used to assess the feasibility of APRETUDE using a four-item measure (1. APRETUDE seems implementable in our clinic/practice, 2. APRETUDE seems possible in our clinic/practice, 3. APRETUDE seems doable in our clinic/practice, 4. APRETUDE seems easy to use in our clinic/practice) and was measured on a five-point rating scale (1 = completely disagree, 2 = disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = completely agree). The mean score was calculated using the 1 to 5 range scale responses on the FIM, and the results are presented in this outcome measure. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI).

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses for the specified items regarding feasibility of APRETUDE implementation.

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses for the specified items regarding clinic capacity for APRETUDE patient management (i.e. "Number of APRETUDE patients that the clinic can manage per week").

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This endpoint presents the results on mean number of staff needed to incorporate APRETUDE into clinics per week.

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to staff time/FTE requirements per week to incorporate APRETUDE.

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice methods for patient tracking.

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice methods to remind patients of an upcoming appointment

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to clinic/practice approaches for offering injection appointments.

The ISQ used a variety of questions to assess SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the feasibility of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to perceived ease/difficulty of implementing APRETUDE in clinics.

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to acceptability of APRETUDE implementation.

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to perceived positive perception of implementing APRETUDE.

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to patient time in waiting room and exam room for APRETUDE injection visits.

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP perceptions on the acceptability of APRETUDE gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with responses to post-injection observation period for patients after APRETUDE.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to convenience level of clinic hours.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to sources of first injection appointment reminders at baseline.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to sources of injection appointment reminders at Month 12.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to preferred appointment reminder types at baseline (Month 1).

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to most helpful types of appointment reminders at M4 and M12.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to need for additional care for injection visits.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to anticipated time off work for APRETUDE injections at baseline.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to time off work for APRETUDE injections at M4 and M12.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to amount of time off work taken for injections at M4 and M12.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to status of time off work for injections at M4 and M12.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to frequency of worry about forgetting APRETUDE injections.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to perceived ease/difficulty of scheduling injection appointments.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to perceived ease/difficulty of rescheduling injection appointments.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to how easy or difficult it has been to get to the clinic every 2 months at M4 and M12.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's feasibility were gathered via the ISQ. Timeframe for evaluation of this outcome measure M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to "Approximately how long has it taken you to get to the clinic/practice from your home to receive your injection?" at M12.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to concerns about APRETUDE.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at baseline (M1).

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at M4.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents data only from the subset of PSPs that had concerns about APRETUDE at M12.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL, M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of bi-monthly clinic visits for injections.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of HIV and STI testing frequency.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to local reactions following an APRETUDE injection.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of local reactions following an APRETUDE injection.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses on return to daily activities post-injection (e.g., going back to work, social events, exercise, driving).

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents data indicating how bothered by pain PSPs were during injection.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to acceptability of injection-related pain.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses to pain reduction strategies post-injection.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents the PSPs mean rating of pain/discomfort following first APRETUDE injection. The rating of pain/discomfort uses a 10-point scale, where 0=No pain and 10=Extreme pain. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP perceptions of the APRETUDE's acceptability were gathered via the ISQ. This outcome measure presents the PSPs mean rating of pain/discomfort following the most recent APRETUDE injection. The rating of pain/discomfort uses a 10-point scale, where 0=No pain and 10=Extreme pain. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for PSPs who received OLI).

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE.

Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. SSP perceptions of the acceptability of APRETUDE implementation were gathered using SSIs. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with influences on and facilitators/barriers of acceptability of APRETUDE.

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE.

Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). SSP perceptions of the feasibility of APRETUDE implementation were gathered using SSIs.

Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs with influences on and facilitators/barriers of feasibility of APRETUDE.

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the acceptability of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with influences of acceptability of APRETUDE at baseline (M1). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the acceptability of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with influences of acceptability of APRETUDE at M12.

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the feasibility of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with influences of feasibility of APRETUDE at baseline (M1). This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection.

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP perceptions of the feasibility of APRETUDE were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with influences of feasibility of APRETUDE at M12.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of use of oral cabotegravir pills as oral lead-in to APRETUDE injections was gathered using the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs who had OLI before APRETUDE injection.

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported use of oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the SSPs who chose OLI before APRETUDE injection at baseline (M1).

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported use of oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs who chose OLI before APRETUDE injection at M4 and M12.

SSI guides were designed to support discussion surrounding the experience of SSPs implementing and administering APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. SSP perceptions on reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered using SSIs. Timeframe for evaluation of this outcome measure is M4 and M12 (equivalent to M5 and M13 for SSPs who assessed PSPs receiving OLI). SSIs were not conducted with SSPs at BL. This outcome measure presents the SSPs with responses on reasons for decision to use OLI assessed by SSI at M4 and M12.

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at baseline (M1).

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is M4 (equivalent to M5 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at M4.

The ISQ used a variety of questions to assess among SSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other considerations related to the use of APRETUDE at their site. SSP self-reported reasons for using oral cabotegravir pills with patient participants as OLI before APRETUDE injection were gathered through the ISQ. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for SSPs who assessed PSPs receiving OLI). This outcome measure presents the SSPs on reasons for decision to use OLI, assessed at M12.

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. PSP self-reported reasons for using oral cabotegravir pills as OLI to APRETUDE injections were gathered using SSIs. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs' experiences with and reasons for using OLI or direct-to-injection (DTI) approach, assessed by SSIs.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they used oral cabotegravir pills as OLI to APRETUDE injections was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs on reasons for decision to use OLI, assessed by surveys.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they used oral cabotegravir pills as OLI to APRETUDE injections was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses on reasons for decision for use of OLI, assessed by surveys.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. Timeframe for evaluation of this outcome measure is BL.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. This outcome measure presents the PSPs responses to consistency in Oral PrEP use in past 6 months.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of their history of oral PrEP use before study participation was gathered via the ISQ at BL alone. This outcome measure presents the PSPs responses to Oral PrEP duration.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. PSP use of the sexual health assessment (available only to the ECI arm) was gathered via the ISQ. Timeframe for evaluation of this outcome measure is at Baseline (BL) and M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs who completed a SHA and initiate APRETUDE. All PSPs enrolled in the study initiated APRETUDE.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to experiences with Oral PrEP, assessed by surveys.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to Oral PrEP side effects, assessed by surveys.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to frequency of worry about Oral PrEP disclosure, assessed by surveys.

The ISQ used a variety of questions to assess among PSPs demographic characteristics, implementation outcomes (e.g., facilitators and barriers, appropriateness, acceptability, feasibility), perceptions of APRETUDE, use of study tools, and other experiences related to receipt of APRETUDE. Self-report from PSPs of the reasons they chose to receive APRETUDE injections, including reasons for switching from oral PrEP to APRETUDE if relevant, was gathered via the ISQ. Timeframe for evaluation of this outcome measure is BL. This outcome measure presents the PSPs with responses to reasons for choosing APRETUDE, assessed by surveys.

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the CFIR. PSP self-reported reasons choosing to receive APRETUDE, including reasons for switching from oral PrEP to APRETUDE if relevant, were gathered using SSIs. This outcome measure presents common concepts identified from qualitative analysis of interview data. The categories below are neither mutually exclusive nor exhaustive, given the variation in probe exposure and discussion patterns inherent to semi-structured qualitative data collection. This outcome measure presents the PSPs with responses for choosing or switching to APRETUDE, assessed by SSI at baseline (M1).

SSI guides were designed to support discussion surrounding the experience of PSPs receiving APRETUDE. Interview guides were informed by the implementation science frameworks from Proctor and the Consolidated Framework for Implementation Research (CFIR). PSP self-reported reasons choosing to receive APRETUDE, including reasons for switching from oral PrEP to APRETUDE if relevant, were gathered using SSIs. Timeframe for evaluation of this outcome measure is M12 (equivalent to M13 for PSPs who received OLI). This outcome measure presents the PSPs with responses for choosing or switching to APRETUDE, assessed by SSI at M12.